These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 21753772)
21. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152 [TBL] [Abstract][Full Text] [Related]
22. Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study. Matsui K; Kim-Mitsuyama S; Ogawa H; Jinnouchi T; Jinnouchi H; Arakawa K; Hypertens Res; 2014 Jun; 37(6):526-32. PubMed ID: 24599010 [TBL] [Abstract][Full Text] [Related]
23. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251 [TBL] [Abstract][Full Text] [Related]
24. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Shimada K; Ogihara T; Saruta T; Kuramoto K; Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495 [TBL] [Abstract][Full Text] [Related]
25. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017 [TBL] [Abstract][Full Text] [Related]
29. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Nakamura T; Inoue T; Fujiwara N; Kawagoe Y; Sugaya T; Ueda Y; Koide H; Node K Clin Nephrol; 2008 Nov; 70(5):385-92. PubMed ID: 19000538 [TBL] [Abstract][Full Text] [Related]
30. A recipe for reducing blood pressure variability: adding blood flow to the mix. Tzeng YC; MacRae B; Rickards C Hypertension; 2012 Aug; 60(2):e12; author reply e13. PubMed ID: 22733457 [No Abstract] [Full Text] [Related]
31. Reduction of albuminuria with antihypertensive treatment: is more always better? Palatini P Am J Hypertens; 2011 Apr; 24(4):377-8. PubMed ID: 21423131 [No Abstract] [Full Text] [Related]
32. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria. Ando K; Haneda M; Ito S; Kashihara N; Node K; Nangaku M; Shimosawa T; Kishimoto J; Fujita T Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969 [TBL] [Abstract][Full Text] [Related]
33. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356 [TBL] [Abstract][Full Text] [Related]
34. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693 [TBL] [Abstract][Full Text] [Related]
35. Why COLM and ACCOMPLISH study results differ. Cífková R J Hypertens; 2014 Oct; 32(10):1967-9. PubMed ID: 25186528 [No Abstract] [Full Text] [Related]
36. Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. Doi M; Miyoshi T; Hirohata S; Kamikawa S; Usui S; Kaji Y; Sakane K; Ogawa H; Ninomiya Y; Kusachi S Am J Med Sci; 2010 May; 339(5):433-9. PubMed ID: 20234301 [TBL] [Abstract][Full Text] [Related]
37. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T; Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534 [TBL] [Abstract][Full Text] [Related]
38. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047 [TBL] [Abstract][Full Text] [Related]
39. Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study. Ritz E; Menne J; Haller H Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv28-30. PubMed ID: 23258807 [No Abstract] [Full Text] [Related]
40. Two amlodipine/ARB combinations for hypertension. Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]